Quick Answer
UNITED THERAPEUTICS Corp reported Diluted EPS of $27.86 per share for fiscal year 2025.
UNITED THERAPEUTICS Corp Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $27.86 | +13.1% |
| 2024 | $24.64 | +24.4% |
| 2023 | $19.81 | +32.1% |
| 2022 | $15.00 | +49.1% |
| 2021 | $10.06 | -12.8% |
| 2020 | $11.54 | +582.8% |
| 2019 | -$2.39 | -117.8% |
| 2018 | $13.39 | +43.8% |
| 2017 | $9.31 | -39.0% |
| 2016 | $15.25 | +19.9% |
| 2015 | $12.72 | +102.5% |
| 2014 | $6.28 | +91.5% |
| 2013 | $3.28 | -42.6% |
| 2012 | $5.71 | +55.6% |
| 2011 | $3.67 | +106.2% |
| 2010 | $1.78 | +408.6% |
| 2009 | $0.35 | +132.4% |
| 2008 | -$1.08 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.16 | +12.1% | +11.7% |
| June 30, 2025 | $6.41 | +9.6% | -3.3% |
| March 31, 2025 | $6.63 | +7.5% | +3.8% |
| September 30, 2024 | $6.39 | +18.8% | +9.2% |
| June 30, 2024 | $5.85 | +11.6% | -5.2% |
| March 31, 2024 | $6.17 | +27.0% | +14.7% |
| September 30, 2023 | $5.38 | +9.6% | +2.7% |
| June 30, 2023 | $5.24 | +117.4% | +7.8% |
- UNITED THERAPEUTICS Corp showed an increase of +13.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2008–2025 period, UNITED THERAPEUTICS Corp’s diluted eps has grown by 2679.6% (from $1.08 per share (loss) to $27.86 per share).
- The most recent figure is from UNITED THERAPEUTICS Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: